Hereditary diffuse gastric cancer (HDGC). An overview

• Published in: Clinics and research in hepatology and gastroenterology 2022-04, Vol.46 (4), p.101820-101820, Article 101820
• Main Authors: Taja-Chayeb, L, Vidal-Millán, S, Trejo-Becerril, C, Pérez-Cárdenas, E, Chávez-Blanco, A, Domínguez-Gómez, G, González-Fierro, A, Romo-Pérez, A, Dueñas-González, A
• Format: Article
• Language: English
• Subjects: CDH1; CTNNA1; Diffuse gastric cancer; Gastric cancer; Germline mutations; Hereditary cancer
• ISSN: 2210-7401; 2210-741X
• DOI: 10.1016/j.clinre.2021.101820

•Hereditary diffuse gastric cancer.•Clinical management.•Germline mutations. It is estimated that up to 10% of gastric carcinomas show familial aggregation. In contrast, around 1-3 % (approximately 33,000 yearly) are genuinely hereditary. Hereditary diffuse gastric cancer (HDGC) is a rare malignancy characterized by autosomal dominant inheritance of pathological variants of the CDH1 and CTNNA1 genes encoding the adhesion molecules E-cadherin and α-catenin, respectively. The multifocal nature of the disease and the difficulty of visualizing precursor lesions by endoscopy underscore the need to be aware of this malignancy as surgical prevention can be fully protective. Here, we provide an overview of the main epidemiological, clinical, genetic, and pathological features of HDGC, as well as updated guidelines for its diagnosis, genetic testing, counseling, surveillance, and management. We conclude that HDGC is a rare, highly penetrant disease that is difficult to diagnose and manage, so it is necessary to correctly identify it to offer patients and their families’ adequate management following the recommendations of the IGCL. A critical point is identifying a mutation in HDGC families to determine whether unaffected relatives are at risk for cancer.